Publicacións en colaboración con investigadores/as de Indiana University School of Medicine - Lafayette (15)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2021

  1. A polygenic resilience score moderates the genetic risk for schizophrenia

    Molecular Psychiatry, Vol. 26, Núm. 3, pp. 800-815

  2. Consultation on kidney stones, Copenhagen 2019: lithotripsy in percutaneous nephrolithotomy

    World Journal of Urology, Vol. 39, Núm. 6, pp. 1663-1670

  3. Erratum: Correction to: Consultation on kidney stones, Copenhagen 2019: lithotripsy in percutaneous nephrolithotomy (World journal of urology (2021) 39 6 (1663-1670))

    World journal of urology

2020

  1. Correction to: Consultation on kidney stones, Copenhagen 2019: lithotripsy in percutaneous nephrolithotomy (World Journal of Urology, (2020), 10.1007/s00345-020-03383-w)

    World Journal of Urology

2019

  1. Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (Nature Genetics, (2019), 51, 3, (414-430), 10.1038/s41588-019-0358-2)

    Nature Genetics

  2. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen

    Nature Communications, Vol. 10, Núm. 1

  3. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing

    Nature Genetics, Vol. 51, Núm. 3, pp. 414-430

2016

  1. Genetic influences on schizophrenia and subcortical brain volumes: Large-scale proof of concept

    Nature Neuroscience, Vol. 19, Núm. 3, pp. 420-431

2015

  1. Mudd's disease (MAT I/III deficiency): A survey of data for MAT1A homozygotes and compound heterozygotes

    Orphanet Journal of Rare Diseases, Vol. 10, Núm. 1

2011

  1. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project

    Genetics in Medicine, Vol. 13, Núm. 3, pp. 230-254

1998

  1. Acute changes in free-fatty acids (FFA) do not alter serum leptin levels

    Journal of Endocrinological Investigation, Vol. 21, Núm. 8, pp. 526-530

  2. Interaction between leptin and neuropeptide Y on in vivo growth hormone secretion

    Neuroendocrinology, Vol. 68, Núm. 3, pp. 187-191

1997

  1. Nocturnal rise of leptin in normal prepubertal and pubertal children and in patients with perinatal stalk-transection syndrome

    Journal of Clinical Endocrinology and Metabolism, Vol. 82, Núm. 8, pp. 2751-2754